Omeprazole Patent Expiration
Omeprazole was first introduced by Astrazeneca Pharmaceuticals Lp
Omeprazole Patents
Given below is the list of patents protecting Omeprazole, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Omeprazole | US10076494 | Stable orally disintegrating pharmaceutical compositions | Dec 08, 2036 | Dexcel |
| Omeprazole | US10835488 | Stable orally disintegrating pharmaceutical compositions | Dec 08, 2036 | Dexcel |
| Omeprazole | US12599565 | Stable Benzimidazole Formulation | Jan 31, 2030 | Dexcel Pharma |
| Omeprazole | US9023391 | Stable benzimidazole formulation |
Aug 16, 2025
(Expired) | Dexcel Pharma |
| Prilosec |
US6150380 (Pediatric) | Crystalline form of omeprazole |
May 10, 2019
(Expired) | Astrazeneca |
| Prilosec |
US6147103 (Pediatric) | Omeprazole process and compositions thereof |
Apr 09, 2019
(Expired) | Astrazeneca |
| Prilosec |
US6166213 (Pediatric) | Omeprazole process and compositions thereof |
Apr 09, 2019
(Expired) | Astrazeneca |
| Prilosec |
US6191148 (Pediatric) | Omerazole process and compositions thereof |
Apr 09, 2019
(Expired) | Astrazeneca |
| Prilosec | US6150380 | Crystalline form of omeprazole |
Nov 10, 2018
(Expired) | Astrazeneca |
| Prilosec | US6147103 | Omeprazole process and compositions thereof |
Oct 09, 2018
(Expired) | Astrazeneca |
| Prilosec | US6166213 | Omeprazole process and compositions thereof |
Oct 09, 2018
(Expired) | Astrazeneca |
| Prilosec | US6191148 | Omerazole process and compositions thereof |
Oct 09, 2018
(Expired) | Astrazeneca |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Omeprazole's patents.
Latest Legal Activities on Omeprazole's Patents
Given below is the list recent legal activities going on the following patents of Omeprazole.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Mar, 2026 | US10076494 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 May, 2024 | US10835488 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 26 Oct, 2022 | US9023391(Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Feb, 2022 | US10076494 |
| Recordation of Patent Grant Mailed Critical
| 17 Nov, 2020 | US10835488 |
| Patent Issue Date Used in PTA Calculation Critical
| 17 Nov, 2020 | US10835488 |
| Email Notification Critical
| 29 Oct, 2020 | US10835488 |
| Issue Notification Mailed Critical
| 28 Oct, 2020 | US10835488 |
| Mailing Corrected Notice of Allowability | 13 Oct, 2020 | US10835488 |
| Email Notification Critical
| 13 Oct, 2020 | US10835488 |
About Veterinary Omeprazole
Omeprazole is used in drugs marketed by 2 different companies: Bimeda Animal Health Ltd, Boehringer Lngelheim Animal Health Usa Inc.
Other drugs containing Omeprazole are: Gastrogard , Gastrobim , Ulcergard .
Omeprazole Petitions
Details of Omeprazole's suitability petitions are listed below.
| Petitioner | Action | Date of Action | Description |
|---|---|---|---|
 | |||
| Aurora Pharmaceutical, LLC | Denied | ||
| Dinsmore & Shohl, LLP | Approved | ||
| Precision Consultants, Inc. | Denied | ||
| Intervet, Inc. | Approved | ||
Omeprazole's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Omeprazole:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
